Welcome to our dedicated page for Chinook Therapeutics news (Ticker: KDNY), a resource for investors and traders seeking the latest updates and insights on Chinook Therapeutics stock.
Chinook Therapeutics, Inc. (NASDAQ: KDNY) is a clinical-stage biotechnology company focused on developing precision medicines specifically for kidney diseases. Kidney diseases pose a significant and growing health challenge globally, often requiring costly treatments like dialysis and transplantation. Chinook is at the forefront of addressing this need through advanced understanding of disease biology and cutting-edge translational platforms.
The company’s lead product candidates include atrasentan, a phase 3 endothelin receptor antagonist aimed at treating IgA nephropathy and proteinuric glomerular diseases, and zigakibart (BION-1301), an anti-APRIL monoclonal antibody undergoing a phase 1/2 trial for IgA nephropathy. Additionally, CHK-336, an oral small molecule LDHA inhibitor, is being developed for hyperoxalurias and other kidney stone disorders, currently in phase 1 trials.
Recent achievements highlight their commitment to innovation. Data from the phase 1 study of CHK-336 demonstrated hepatic LDH target engagement and decreased oxalate production, albeit with ongoing investigations into observed serious adverse events. The initiation of the phase 3 BEYOND study for zigakibart marks another milestone in providing new treatment options for patients with IgAN, reinforcing the potential of their therapies to modify disease progression.
Chinook’s approach leverages data from comprehensive kidney single-cell RNA sequencing and large chronic kidney disease (CKD) patient cohorts to identify key therapeutic targets. This strategy enables them to build a robust pipeline of precision medicines for rare and severe kidney diseases. Their research benefits from rich clinical data and patient samples, providing insights that drive the development of their innovative drug candidates.
Financially, Chinook remains focused on advancing its clinical programs while exploring strategic collaborations and partnerships to bolster its development efforts. Their strong scientific foundation and strategic focus positions them as a leader in the field of kidney disease therapeutics.
For more detailed updates and ongoing news, visit their official website at www.chinooktx.com.
Chinook Therapeutics (NASDAQ: KDNY) has announced significant upcoming presentations regarding its kidney disease treatments at major conferences. From April 15-19, 2021, the ISN World Congress of Nephrology will feature data on the Gd-IgA1 biomarker from the phase 1 study of BION-1301. Additionally, the 58th ERA-EDTA Congress from June 5-8, 2021, will present interim results on IgA nephropathy treatments. The lead product, atrasentan, is in phase 3 trials for IgA nephropathy, highlighting Chinook's commitment to advancing precision medicines for serious kidney conditions.
Chinook Therapeutics (NASDAQ: KDNY) announced the enrollment of the first patient in its ALIGN Study, a pivotal Phase 3 trial assessing the efficacy of atrasentan for treating IgA nephropathy (IgAN). This milestone follows previous studies indicating atrasentan's capacity to reduce proteinuria by 30-35% and improve kidney function. The ALIGN Study aims to involve 320 patients and will measure the drug's impact over approximately 2.5 years, with top-line data expected in 2023. IgAN is a leading cause of chronic kidney disease, highlighting the urgency for effective treatments.
Chinook Therapeutics, Inc. (NASDAQ: KDNY) announced participation in two upcoming virtual investor conferences. The H.C. Wainwright Global Life Sciences Conference will feature an on-demand fireside chat starting March 9 at 7:00 am EST, while the Oppenheimer 31st Annual Healthcare Conference is set for March 16 at 1:50 pm EST. Archived recordings of these presentations will be available for 90 days on Chinook’s website. The company focuses on precision medicines for kidney diseases, with key programs targeting conditions like IgA nephropathy.
Chinook Therapeutics (NASDAQ: KDNY) and Evotec SE have announced a strategic collaboration aimed at developing novel precision medicine therapies for chronic kidney diseases, specifically targeting polycystic kidney disease (PKD), lupus nephritis, and IgA nephropathy. This partnership will utilize Evotec's NURTuRE patient biobank and PanHunter Multi-Omics Platform to characterize molecular drivers and validate new therapeutic targets. Chinook will lead clinical development, while Evotec will receive an upfront payment, research funding, and royalties on sales from developed products.
Chinook Therapeutics (NASDAQ: KDNY) announced that Andrew King, D.V.M., Ph.D., Head of Renal Discovery, will present at the 3rd Annual Chronic Kidney Disease Drug Development (CKD3) Summit. His presentation on the selective ETA receptor antagonist atrasentan is scheduled for March 4, 2021. Dr. King will also participate in a panel on precision medicine on March 3, 2021. The virtual summit runs from March 2-4, 2021, focusing on kidney disease drug development.
Chinook Therapeutics, Inc. (NASDAQ: KDNY) announced participation in a virtual fireside chat at the 10th Annual SVB Leerink Global Healthcare Conference on February 24, 2021, at 10:00 am ET. The event will provide insights into the company's focus on precision medicines for kidney diseases, including lead programs like atrasentan and BION-1301. A replay of the presentation will be available on Chinook’s website for 90 days following the event.
Chinook Therapeutics (NASDAQ: KDNY) announced participation in key virtual investor conferences scheduled for January 2021. Notable events include the H.C. Wainwright Bioconnect 2021 Conference on January 11 and the 39th Annual J.P. Morgan Healthcare Conference on January 12. Additionally, 1x1 meetings will occur from January 11 to January 14. Interested investors can access live webcasts and archived recordings through Chinook's website for 30 days. The company focuses on precision medicines for kidney diseases, including its lead program, atrasentan, for IgA nephropathy.
Chinook Therapeutics (NASDAQ: KDNY) has signed a license agreement with Morehouse School of Medicine to develop therapeutics for kidney diseases, particularly those affecting underserved communities. This agreement grants Chinook exclusive rights to certain patents for methods and compositions targeting conditions like HIV-associated nephropathy and focal segmental glomerulosclerosis. The terms of the license remain undisclosed. Chinook aims to enhance its intellectual property portfolio to improve health outcomes for patients in need.
Chinook Therapeutics (NASDAQ: KDNY) announced the approval of a stock options grant for CFO Eric Bjerkholt totaling 147,477 shares. This Inducement Grant, effective November 30, 2020, aligns with the company's 2015 Equity Incentive Plan, featuring an exercise price of $13.98 per share. The options vest over four years, with 25% vesting on November 16, 2021. This grant complies with Nasdaq Rule 5635(c)(4) as a material inducement for his employment with Chinook.
Chinook specializes in precision medicines for kidney diseases, with key programs in IgA nephropathy and primary hyperoxaluria.
Chinook Therapeutics, a clinical-stage biotechnology company focused on kidney diseases, announced participation in upcoming virtual investor conferences. The company will present at the Piper Sandler 32nd Annual Virtual Healthcare Conference from November 23 to December 3 and at the Evercore ISI 3rd Annual HealthCONx Conference on December 1 at 11:20 am EST. Additionally, 1x1 meetings are scheduled from December 1 to 3. Archived presentations will be available for 90 days on Chinook’s website.
FAQ
What is the market cap of Chinook Therapeutics (KDNY)?
What is Chinook Therapeutics, Inc.?
What are the main products of Chinook Therapeutics?
What recent achievements has Chinook Therapeutics made?
What is the BEYOND study?
How does Chinook Therapeutics develop its medicines?
Where can I find more information about Chinook Therapeutics?
What are the goals of Chinook Therapeutics' clinical programs?
What are the potential benefits of Chinook's drug candidates?
How does Chinook Therapeutics contribute to kidney disease treatment?
What is the significance of CHK-336?
